| pubmed-article:7743612 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7743612 | lifeskim:mentions | umls-concept:C0011071 | lld:lifeskim |
| pubmed-article:7743612 | lifeskim:mentions | umls-concept:C0036442 | lld:lifeskim |
| pubmed-article:7743612 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:7743612 | lifeskim:mentions | umls-concept:C1545588 | lld:lifeskim |
| pubmed-article:7743612 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:7743612 | lifeskim:mentions | umls-concept:C2745888 | lld:lifeskim |
| pubmed-article:7743612 | lifeskim:mentions | umls-concept:C1533148 | lld:lifeskim |
| pubmed-article:7743612 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:7743612 | pubmed:dateCreated | 1995-6-15 | lld:pubmed |
| pubmed-article:7743612 | pubmed:abstractText | Low-dose scopolamine increases heart rate variability (HRV) in patients with a prior myocardial infarction (MI). This observation, combined with the evidence that elevated cardiac vagal activity during acute myocardial ischemia is antifibrillatory, has generated the hypothesis that scopolamine might be protective after MI. We tested low-dose scopolamine in a clinically relevant experimental preparation for sudden death in which other vagomimetic interventions are effective. | lld:pubmed |
| pubmed-article:7743612 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743612 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743612 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7743612 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743612 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7743612 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743612 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7743612 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7743612 | pubmed:month | May | lld:pubmed |
| pubmed-article:7743612 | pubmed:issn | 0009-7322 | lld:pubmed |
| pubmed-article:7743612 | pubmed:author | pubmed-author:SchwartzP JPJ | lld:pubmed |
| pubmed-article:7743612 | pubmed:author | pubmed-author:ForemanR DRD | lld:pubmed |
| pubmed-article:7743612 | pubmed:author | pubmed-author:AdamsonP BPB | lld:pubmed |
| pubmed-article:7743612 | pubmed:author | pubmed-author:VanoliEE | lld:pubmed |
| pubmed-article:7743612 | pubmed:author | pubmed-author:De FerrariG... | lld:pubmed |
| pubmed-article:7743612 | pubmed:author | pubmed-author:HullS SSSJr | lld:pubmed |
| pubmed-article:7743612 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7743612 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:7743612 | pubmed:volume | 91 | lld:pubmed |
| pubmed-article:7743612 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7743612 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7743612 | pubmed:pagination | 2516-9 | lld:pubmed |
| pubmed-article:7743612 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:meshHeading | pubmed-meshheading:7743612-... | lld:pubmed |
| pubmed-article:7743612 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7743612 | pubmed:articleTitle | Do increases in markers of vagal activity imply protection from sudden death? The case of scopolamine. | lld:pubmed |
| pubmed-article:7743612 | pubmed:affiliation | Department of Physiology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA. | lld:pubmed |
| pubmed-article:7743612 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7743612 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:7743612 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7743612 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7743612 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7743612 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7743612 | lld:pubmed |
